Date	Article
18 Dec 2003	Oxford BioMedica Oncology Update
15 Dec 2003	Oxford BioMedica Presents Proof-of-Principle Data for its Innurex® Nerve Repair Programme at the 10th International Symposium on Neural Regeneration
27 Nov 2003	Oxford BioMedica Secures Funding from The Foundation Fighting Blindness
13 Nov 2003	Oxford BioMedica Reports Promising Preclinical Results with MoNuDin™ in the Treatment of Motor Neuron Disease
24 Oct 2003	Oxford BioMedica Receives Approval from GTAC for Metxia® to Enter Clinical Trials in Pancreatic Cancer
2 Oct 2003	Result of EGM
16 Sep 2003	Fully Underwritten Rights Issue to Raise Approximately £20 Million Net
16 Sep 2003	Oxford BioMedica Interim Results for the Six Months Ended 30 June 2003
9 Sep 2003	Oxford BioMedica and EntreMed Enter Agreement on RetinoStat® Programme
28 Aug 2003	Cancer Research UK Supports Additional TroVax Phase II Trial in Colorectal Cancer
13 Aug 2003	Oxford BioMedica Obtains Further Fundamental Patent for LentiViral Gene Therapy Technology
14 Jul 2003	Second TroVax Phase I/II Trial Results Presented at the 94th Annual Meeting of the American Association for Cancer Research
3 Jul 2003	Positive Results from MetXia Phase I/II Breast Cancer Trial and Plans for Pancreactic Cancer Trial
23 Jun 2003	Oxford BioMedica Describes the Manufacturing Process for Prosavin at Bio2003
20 May 2003	Oxford BioMedica’s TroVax® Receives Clearance from the United States Recombinant DNA Advisory Committee
6 May 2003	Oxford BioMedica and the Institute of Ophthalmology Present Preclinical Results from the RetinoStat® Programme
15 Apr 2003	Oxford BioMedica - Company Update at AGM
18 Mar 2003	Agreement With Viragen Inc Re. Licence to LentiVector® Technology
4 Mar 2003	Wyeth Exercises Option on Oxford BioMedica's Anti-tumour Antibody
4 Mar 2003	Oxford BioMedica plc (LSE:OXB) Preliminary Results for the Year Ended 31 December 2002
3 Mar 2003	Oxford BioMedica Obtains Approval for TroVax® to Enter Phase II Trials for Colorectal Cancer
11 Feb 2003	Oxford BioMedica Awarded €900,000 Grant
28 Jan 2003	Oxford BioMedica and Kiadis Agree Collaborative Programme on Wound Healing
6 Jan 2003	Oxford BioMedica plc - Research & Development Agreement with Intervet Pharma

Website by College Hill - Life Sciences